Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (581-590 of 688) with videos related to

Pageof 69
Sort By:
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Circulation|September 29, 2024
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF TrialKieran F Docherty, Alasdair D Henderson, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|July 30, 2025
Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF TrialMuthiah Vaduganathan, Brian L Claggett, Jacob A Udell, et al.
JACC. Heart Failure|April 15, 2025
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF TrialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Journal of Cardiac Failure|May 13, 2024
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart FailureJohn W Ostrominski, Rahul Aggarwal, Brian L Claggett, et al.
Circulation. Heart Failure|December 12, 2012
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesisLili Yu, Willem P T Ruifrok, Maxi Meissner, et al.
JACC. Heart Failure|August 26, 2025
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection FractionHenri Lu, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 69

Showing results (581-590 of 688) with videos related to

Sort By:
Pageof 69
Journal of the American College of Cardiology|August 27, 2025
Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Participant-Level Pooled Analysis of Randomized Clinical TrialsJohn W Ostrominski, Mats C Højbjerg Lassen, Jawad H Butt, et al.
Journal of the American College of Cardiology|September 2, 2025
Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection FractionJohn W Ostrominski, Brendon L Neuen, Brian L Claggett, et al.
Circulation|September 29, 2024
Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF TrialKieran F Docherty, Alasdair D Henderson, Pardeep S Jhund, et al.
Journal of the American College of Cardiology|July 30, 2025
Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF TrialMuthiah Vaduganathan, Brian L Claggett, Jacob A Udell, et al.
JACC. Heart Failure|April 15, 2025
Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF TrialJohn W Ostrominski, Muthiah Vaduganathan, Brian L Claggett, et al.
Diabetes, Obesity & Metabolism|February 19, 2021
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trialMichael E Nassif, Sheryl L Windsor, Fengming Tang, et al.
Journal of the American College of Cardiology|August 3, 2019
Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection FractionJasper Tromp, Li Shen, Pardeep S Jhund, et al.
Journal of Cardiac Failure|May 13, 2024
Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart FailureJohn W Ostrominski, Rahul Aggarwal, Brian L Claggett, et al.
Circulation. Heart Failure|December 12, 2012
Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesisLili Yu, Willem P T Ruifrok, Maxi Meissner, et al.
JACC. Heart Failure|August 26, 2025
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection FractionHenri Lu, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 69